Comprehensive Report on AZD-5069: A CXCR2 Antagonist in Clinical Development

Executive Summary

AZD-5069 is an investigational, orally bioavailable, small-molecule drug identified as a potent, selective, and reversible antagonist of the C-X-C chemokine receptor 2 (CXCR2). The primary mechanism of action involves the direct binding to and inhibition of CXCR2, a G protein-coupled receptor predominantly expressed on the surface of neutrophils. This action effectively blocks the receptor's activation by its cognate ligands, such as CXCL1 and CXCL8 (IL-8), thereby inhibiting the downstream signaling cascades that mediate neutrophil chemotaxis and recruitment to sites of inflammation and tissue injury.

The clinical development of AZD-5069 has followed a distinct, bifurcated trajectory. The initial therapeutic strategy focused on its potential as an anti-inflammatory agent for neutrophil-driven respiratory diseases, including chronic obstructive pulmonary disease (COPD), non-cystic fibrosis bronchiectasis, and severe, uncontrolled asthma. In these indications, clinical trials consistently demonstrated robust and statistically significant pharmacodynamic activity; treatment with AZD-5069 led to a marked reduction in neutrophil counts in both peripheral blood and airway sputum. However, this potent biological effect paradoxically failed to translate into measurable clinical efficacy. Multiple Phase II studies concluded that despite successful target engagement, AZD-5069 did not improve key clinical outcomes such as lung function, symptom scores, or the rate of exacerbations. This critical disconnect between biomarker modulation and clinical benefit led to the discontinuation of its development for inflammatory respiratory conditions.

Based on an evolving understanding of tumor immunology, the development program for AZD-5069 was strategically repurposed for oncology. The scientific rationale for this pivot is centered on the critical role of the CXCR2 axis in shaping an immunosuppressive tumor microenvironment (TME). CXCR2 signaling is a key pathway for the recruitment of pro-tumorigenic myeloid cells, including myeloid-derived suppressor cells (MDSCs) and tumor-associated neutrophils (TANs), into the TME. These cells contribute to tumor growth, angiogenesis, metastasis, and, crucially, resistance to various anti-cancer therapies, including immunotherapy and hormone therapy. The therapeutic hypothesis posits that by blocking CXCR2, AZD-5069 can inhibit the infiltration of these immunosuppressive cells, thereby "reprogramming" the TME to be more permissive to anti-tumor immune responses and rendering tumors more sensitive to concomitant cancer treatments.

Clinical investigations in oncology have yielded promising results that support this new therapeutic strategy. A Phase I/II trial (ACE) in patients with metastatic castration-resistant prostate cancer (mCRPC) demonstrated that the combination of AZD-5069 with the androgen receptor antagonist enzalutamide was tolerable and resulted in objective clinical responses, including tumor shrinkage and significant PSA declines in a subset of patients who had previously progressed on hormone therapy. This provided the first human proof-of-concept that CXCR2 inhibition could reverse endocrine resistance. Further investigations are ongoing, including a Phase I/II study (CUBIC) combining AZD-5069 with the PD-L1 inhibitor durvalumab in advanced hepatocellular carcinoma (HCC), and a study in other advanced solid malignancies.

Throughout its extensive clinical evaluation, AZD-5069 has maintained a consistent and manageable safety profile. The most prominent and expected adverse event is a dose-dependent, on-target, and reversible neutropenia. Critically, and in alignment with preclinical toxicology data, this reduction in circulating neutrophils has not been associated with an increased risk of infection. This favorable safety attribute is attributed to the drug's highly selective mechanism, which inhibits CXCR2-mediated inflammatory recruitment while preserving the fundamental antimicrobial functions of neutrophils, such as phagocytosis and oxidative burst. This profile makes AZD-5069 a particularly attractive candidate for combination therapies in oncology, where maintaining host immunocompetence is paramount. The future of AZD-5069 lies in its potential as a TME-modulating agent, used not as a monotherapy but as a synergistic partner to overcome resistance and enhance the efficacy of established anti-cancer agents in rationally selected patient populations.

I. Introduction to AZD-5069: An Investigational CXCR2 Antagonist

1.1. The CXCR2-CXCL Axis: A Key Mediator of Neutrophil Chemotaxis

[The C-X-C chemokine receptor 2 (CXCR2) is a class A, rhodopsin-like G protein-coupled receptor (GPCR) that serves as a central regulator of innate immune responses, primarily through its control of neutrophil trafficking.][1][ It is expressed at high levels on the surface of neutrophils, but also to a lesser extent on other cell types, including monocytes, mast cells, and some endothelial and epithelial cells.][4][ The primary function of CXCR2 is to bind a specific subset of C-X-C chemokines characterized by an N-terminal glutamic acid-leucine-arginine (ELR) motif.][3][ Key ligands in humans include CXCL1 (growth-related oncogene-alpha, GRO-α), CXCL2 (GRO-β), CXCL3 (GRO-γ), CXCL5 (epithelial-neutrophil activating peptide-78, ENA-78), CXCL6 (granulocyte chemotactic protein-2, GCP-2), CXCL7 (neutrophil-activating peptide-2, NAP-2), and, most notably, CXCL8 (interleukin-8, IL-8).][1]

[Upon ligand binding, CXCR2 undergoes a conformational change that activates its associated heterotrimeric G proteins. This activation leads to the dissociation of the G-protein subunits, which in turn trigger multiple downstream intracellular signaling pathways, including those mediated by phosphatidylinositol 3-kinase (PI3K), phospholipase C (PLC), and the p38 mitogen-activated protein kinase (p38MAPK) cascade.][2][ The culmination of this signaling is a coordinated cellular response in neutrophils that includes chemotaxis (directed migration along a chemokine gradient), degranulation (release of antimicrobial proteins), upregulation of adhesion molecules, and the production of reactive oxygen species (ROS), all of which are critical for host defense.][1]

[While essential for normal immune surveillance and response to infection, dysregulated or chronic activation of the CXCR2 signaling axis is implicated in the pathophysiology of numerous diseases. In chronic inflammatory conditions such as chronic obstructive pulmonary disease (COPD), severe asthma, and bronchiectasis, persistent CXCR2 signaling drives an unresolving influx of neutrophils into the airways, contributing to mucus hypersecretion, protease-mediated tissue damage, and progressive loss of lung function.][4][ In the context of cancer, tumor cells and stromal cells within the tumor microenvironment (TME) often secrete high levels of CXCR2 ligands. This serves to recruit vast numbers of immunosuppressive myeloid cells, such as MDSCs and TANs, which express CXCR2. The infiltration of these cells into the tumor promotes angiogenesis, suppresses anti-tumor T-cell responses, and directly contributes to tumor growth, metastasis, and the development of therapeutic resistance.][2]

1.2. Rationale for Therapeutic Targeting of CXCR2

[Given its central role in mediating pathological neutrophil recruitment, CXCR2 has emerged as a highly attractive therapeutic target. The guiding hypothesis is that a selective antagonist could block the receptor and disrupt the harmful consequences of its overactivation, offering a targeted anti-inflammatory or immunomodulatory therapy.][6][ In inflammatory diseases, the goal is to reduce the chronic influx of neutrophils into affected tissues, thereby mitigating tissue damage and alleviating symptoms.][7][ In oncology, the rationale is more nuanced: the objective is to inhibit the recruitment of pro-tumorigenic MDSCs and TANs to the TME. This is expected to relieve immunosuppression, enhance the efficacy of other anti-cancer agents like immune checkpoint inhibitors, and potentially reverse acquired drug resistance.][9]

[The development of small-molecule CXCR2 antagonists has been an area of active research for several pharmaceutical companies. Early programs, including initial efforts at AstraZeneca, identified bicyclic compounds that, while potent, were often hampered by poor physicochemical properties such as low solubility and poor oral bioavailability.][12][ This led to the pursuit of next-generation antagonists with improved "drug-like" characteristics. AZD-5069 emerged from these efforts as a novel, monocyclic sulfamide-based compound designed to overcome the limitations of earlier candidates, possessing improved solubility and pharmacokinetic profiles suitable for oral administration.][2]

1.3. AZD-5069: Development Trajectory from Inflammation to Oncology

[AZD-5069 entered clinical development as a potential treatment for inflammatory respiratory diseases where neutrophilic inflammation is a prominent feature.][10] Phase I and II studies were conducted in patients with COPD, bronchiectasis, and severe asthma. These trials successfully demonstrated that AZD-5069 could achieve its intended pharmacodynamic effect—a significant reduction of neutrophils in the airways. However, this biological activity did not translate into clinical benefit, leading to the cessation of its development in these indications.

[Subsequently, a deeper understanding of the role of CXCR2 in cancer biology prompted a strategic pivot. The compelling preclinical evidence that CXCR2 inhibition could modulate the TME and overcome therapeutic resistance provided a strong rationale for repurposing AZD-5069 as an oncology agent.][10] This shift represents a prime example of mechanism-based drug development, where a drug with a well-characterized mechanism of action and a favorable safety profile is redeployed to a disease area where its biological effects are more directly linked to a causal driver of pathology. The remainder of this report will detail the molecular profile, mechanism, and comprehensive clinical development history of AZD-5069, chronicling its journey from a failed respiratory drug to a promising candidate in cancer immunotherapy.

II. Physicochemical Properties and Molecular Profile

AZD-5069 is a synthetic organic, small-molecule compound designed for oral administration. Its chemical structure and properties have been extensively characterized and are consolidated from various public databases and commercial supplier information. The following table provides a comprehensive summary of its key identifiers and physicochemical characteristics, which are foundational to understanding its pharmacological behavior.

Property Category	Parameter	Value / Identifier	Source(s)
General Information	Drug Name	AZD-5069	6
	DrugBank ID	DB16822	6
	Type	Small Molecule	6
	Compound Class	Synthetic organic	16
Chemical Identifiers	CAS Number	878385-84-3	6
	IUPAC Name	N-[(2,3-difluorophenyl)methylsulfanyl]-6-oxypyrimidin-4-yl]azetidine-1-sulfonamide	6
	Other Synonyms	AZD5069, CXCR2 antagonist AZD5069, N-(2-(((2,3-Difluorophenyl)methyl)thio)-6-(((1R,2S)-2,3-dihydroxy-1-methylpropyl)oxy)-4-pyrimidinyl)-1-azetidinesulfonamide	6
Structural Information	Molecular Formula	$C_{18}H_{22}F_{2}N_{4}O_{5}S_{2}$	4
	Molecular Weight	476.5 g/mol	4
	Canonical SMILES	CC(C(CO)O)OC1=NC(=NC(=C1)NS(=O)(=O)N2CCC2)SCC3=C(C(=CC=C3)F)F	17
	Isomeric SMILES	CC@HOC1=NC(=NC(=C1)NS(=O)(=O)N2CCC2)SCC3=C(C(=CC=C3)F)F
	InChI	InChI=1S/C18H22F2N4O5S2/c1-11(14(26)9-25)29-16-8-15(23-31(27,28)24-6-3-7-24)21-18(22-16)30-10-12-4-2-5-13(19)17(12)20/h2,4-5,8,11,14,25-26H,3,6-7,9-10H2,1H3,(H,21,22,23)/t11-,14+/m1/s1
	InChIKey	QZECRCLSIGFCIO-RISCZKNCSA-N
Registry Numbers	UNII	4ADT8JXB9S
	EC Number	688-153-5
	ChEMBL ID	CHEMBL4562140
	NCI Thesaurus Code	C123383
Physicochemical Properties	Topological Polar Surface Area	158.56 $Å^{2}$
	XLogP	1.73
	Hydrogen Bond Donors	3
	Hydrogen Bond Acceptors	8
	Rotatable Bonds	10
	Solubility	Soluble in DMSO
	Formulation	Crystalline solid
Storage and Handling	Recommended Storage	-20°C
	Stability	$\geq$ 4 years
	Sensitivities	Air and light sensitive

III. Mechanism of Action: Selective Antagonism of the CXCR2 Signaling Pathway

3.1. Binding Affinity and Receptor Selectivity

AZD-5069 functions as a direct antagonist of the human CXCR2 receptor. Its high potency has been demonstrated in radioligand binding assays, where it inhibits the binding of $^{125}$I-labeled CXCL8 (IL-8) to human CXCR2 receptors expressed on cell membranes. These experiments have established a pIC$_{50}$ value of 9.1, which corresponds to an IC$_{50}$ (the concentration required to inhibit 50% of binding) of 0.79 nM. This sub-nanomolar potency indicates a very high affinity of the drug for its target receptor.

A critical feature of AZD-5069's pharmacological profile is its high degree of selectivity. The drug exhibits over 150-fold greater selectivity for CXCR2 compared to the closely related C-X-C chemokine receptor 1 (CXCR1) and the C-C chemokine receptor 2b (CCR2b). CXCR1 also binds CXCL8 and is involved in neutrophil activation, but its ligand profile is narrower than that of CXCR2. The high selectivity for CXCR2 is therapeutically important, as it minimizes the potential for off-target effects that could arise from interacting with other chemokine receptors, thereby contributing to a more favorable safety profile. This specificity ensures that the drug's effects are precisely targeted to the CXCR2-mediated signaling pathway.

3.2. Reversibility and Binding Kinetics

[The interaction of AZD-5069 with the CXCR2 receptor is characterized as "slowly reversible". This kinetic property means that once bound, the drug dissociates from the receptor at a slow rate. The binding kinetics and resulting pharmacology are influenced by both time and temperature, as observed in ][in vitro] assays.

[This slow dissociation rate has significant functional consequences. In cellular assays where cells are exposed to the drug for short incubation periods, AZD-5069 exhibits a phenomenon known as insurmountable antagonism. In a classic competitive, reversible antagonism, increasing the concentration of the agonist (e.g., CXCL8) can overcome the effect of the antagonist, resulting in a parallel rightward shift of the agonist's concentration-response curve. With insurmountable antagonism, however, increasing the agonist concentration cannot fully restore the maximal response. Instead, the agonist response curves appear to collapse in the presence of AZD-5069. This behavior suggests that during the timeframe of the functional assay, the drug's dissociation is too slow to allow the system to reach equilibrium, leading to a prolonged and robust blockade of the receptor. This kinetic profile observed ][in vitro][ was also reflected in ][in vivo] models, suggesting that AZD-5069 can provide sustained receptor inhibition after administration.

3.3. Functional Consequences on Neutrophil Activity

The high-affinity and selective binding of AZD-5069 to CXCR2 translates into potent and specific inhibition of neutrophil functions that are directly mediated by this receptor.

Inhibition of Chemotaxis: The primary and most potent functional effect of AZD-5069 is the inhibition of neutrophil chemotaxis. In assays measuring the directed migration of isolated human neutrophils toward a gradient of the CXCR2 ligand CXCL1, AZD-5069 produced a concentration-dependent inhibition with a pA$_{2}$ value (a measure of antagonist potency) estimated to be between 9.1 and 9.6. This potent blockade of chemotaxis is the core mechanism by which AZD-5069 is expected to prevent the harmful accumulation of neutrophils in inflamed tissues or the tumor microenvironment.

Inhibition of Activation Markers: Beyond migration, AZD-5069 also blocks other downstream signaling events triggered by CXCR2 activation. It effectively inhibits the ligand-induced increase in cytosolic calcium concentration in neutrophils, a key second messenger event. Furthermore, it inhibits the upregulation of the integrin CD11b on the neutrophil surface in response to CXCL1 stimulation, with a measured pA$_{2}$ of 6.9. CD11b is a critical adhesion molecule that facilitates neutrophil attachment to the endothelium and subsequent extravasation into tissues.

Specificity of Action:[ The inhibitory effects of AZD-5069 are highly specific to the CXCR2 pathway. When neutrophils were stimulated with various inflammatory mediators, a high concentration of AZD-5069 was found to specifically block only the response driven by the CXCR2 ligand CXCL1. It had no significant inhibitory effect on neutrophil activation (as measured by CD11b expression) when stimulated by non-CXCR2 agonists such as the complement component C5a, the bacterial peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP), or the lipid mediator leukotriene B$][{4}$ (LTB$]{4}$).

[This high degree of mechanistic precision is a defining characteristic of AZD-5069. The drug does not act as a general suppressor of neutrophil function. Instead, it operates as a highly specific inhibitor of neutrophil ][recruitment][ and ][activation] that is initiated through the CXCR2 receptor. This distinction is fundamentally important. Preclinical and clinical studies have confirmed that while AZD-5069 effectively blocks CXCR2-mediated chemotaxis, it leaves other critical neutrophil functions intact. Specifically, pathogen-initiated phagocytosis and the subsequent oxidative burst, which are essential for clearing bacterial infections and rely on different recognition and activation pathways, are preserved during treatment. This mechanistic profile provides a compelling explanation for the key safety finding observed throughout the clinical program: the ability of AZD-5069 to reduce inflammatory neutrophil infiltration without significantly increasing the risk of opportunistic infections. This "scalpel, not sledgehammer" approach allows for the modulation of pathological inflammation while maintaining the integrity of the host's core innate immune defenses, a feature of profound importance for its development as a therapeutic agent, particularly in the oncology setting where patients are often immunocompromised.

IV. Preclinical Pharmacology and Toxicology Profile

4.1. In Vivo Proof-of-Concept in Inflammation Models

[The ][in vivo][ efficacy of AZD-5069 as an anti-inflammatory agent was established in preclinical models of lung inflammation. In a well-characterized rat model, inhalation of lipopolysaccharide (LPS), a component of gram-negative bacteria, induces a robust neutrophilic inflammatory response in the lungs. Oral administration of AZD-5069 to these animals effectively blocked the LPS-induced influx of neutrophils into the bronchoalveolar lavage fluid (BALF). This finding provided critical proof-of-concept, demonstrating that AZD-5069 is orally bioavailable, achieves sufficient systemic exposure to engage its target, and can effectively inhibit neutrophil recruitment to the lungs ][in vivo]. This preclinical evidence formed the basis for its initial clinical development in inflammatory respiratory diseases.

4.2. In Vivo Efficacy in Oncology Models

Following the strategic pivot to oncology, preclinical studies in relevant cancer models provided the foundational rationale for its investigation in human malignancies.

In murine models of non-alcoholic steatohepatitis-associated hepatocellular carcinoma (NASH-HCC), a tumor type often resistant to immune checkpoint inhibitors, the combination of AZD-5069 with an anti-PD-L1 antibody yielded synergistic effects. This combination therapy significantly suppressed tumor burden and extended the survival of the animals compared to either agent alone. Mechanistically, this was associated with a notable shift in the phenotype of tumor-associated neutrophils (TANs) from a pro-tumorigenic state to an anti-tumor, progenitor-like state. These data strongly suggested that blocking CXCR2 could potentiate the efficacy of immunotherapy in "cold" or resistant tumor types and directly informed the design of the CUBIC clinical trial in HCC.

In another line of investigation using xenograft models of prostate cancer with PTEN-deficiency (a common genetic alteration in this disease), AZD-5069 also demonstrated anti-tumor activity. When administered in combination with ionizing radiation, AZD-5069 significantly attenuated tumor growth and progression to a greater extent than radiation therapy alone. This suggests that by blocking the recruitment of myeloid cells that contribute to a pro-survival and repair response after radiation, AZD-5069 can enhance the efficacy of radiotherapy.

4.3. Long-Term Toxicology and Safety Pharmacology

The long-term safety of AZD-5069 was rigorously evaluated in extended toxicology studies, most notably a 39-week study in cynomolgus monkeys. In this study, animals received oral doses of AZD-5069 up to 525 mg/kg/day, resulting in systemic drug exposures that were approximately 2- to 25-fold higher than those achieved with therapeutic doses in humans.

Despite these high exposures, the drug was generally well-tolerated. The primary on-target histopathological finding was a dose-related increment in the myeloid-to-erythroid ratio within the bone marrow, accompanied by an increase in segmented granulocytes. This is a predictable consequence of the drug's mechanism of action, which involves inhibiting the migration of mature neutrophils from the bone marrow into the circulation.

Critically, several key safety observations were made in this long-term study. First, despite the effects on bone marrow composition, there were no compound-related changes in the baseline numbers of circulating neutrophils in the monkeys. Second, and of paramount importance, there was no increased risk of infection observed in the animals chronically treated with AZD-5069 over the entire 39-week period.

[To understand the basis for this preserved host immunity, neutrophils were isolated from the chronically treated monkeys and their core antimicrobial functions were assessed ][ex vivo]. The results were definitive: neutrophils from AZD-5069-treated animals retained their full capacity for pathogen-initiated phagocytosis (the engulfment of bacteria) and oxidative burst (the production of reactive oxygen species to kill pathogens). These preclinical toxicology findings are of immense value, as they provide a strong biological underpinning for the favorable safety profile observed in human clinical trials, particularly the lack of increased infection susceptibility despite the drug's potent effects on neutrophil trafficking.

V. Clinical Pharmacokinetics and Metabolism (ADME)

The pharmacokinetic (PK) profile of AZD-5069 has been thoroughly characterized through a comprehensive Phase I program that included eight distinct studies involving a total of 240 healthy volunteers. These studies assessed single and multiple doses across a wide range, using various oral formulations (solution, suspension, capsules, and tablets), and evaluated the influence of intrinsic and extrinsic factors. The data demonstrate that AZD-5069 possesses a predictable and well-behaved pharmacokinetic profile suitable for clinical development.

Absorption: Following oral administration under fasting conditions, AZD-5069 is rapidly absorbed, with the median time to reach maximum plasma concentration (T${max}$) being approximately 2 hours. An absorption, distribution, metabolism, and excretion (ADME) study using a $^{14}$C-radiolabeled oral solution indicated that at least 65% of the dose is absorbed, based on the total radioactivity recovered in the urine.[14, 28] The presence of a high-fat, high-calorie meal has a notable effect on the rate, but not the extent, of absorption; it delays T${max}$ and reduces the peak plasma concentration (C$_{max}$) by approximately 50%, but the total systemic exposure, as measured by the area under the concentration-time curve (AUC), remains unchanged.

Distribution: AZD-5069 is highly bound to plasma proteins, with a bound fraction of 99%. The geometric mean apparent volume of distribution at steady state (V$_{z}$/F) across studies in adult Caucasian subjects was in the range of 56 to 134 L, indicating distribution into tissues beyond the plasma volume.

Metabolism:[ The drug is extensively metabolized, as metabolism is the primary route of its elimination. Less than 5-10% of an administered oral dose is excreted as the unchanged parent drug in urine and feces. ][In vitro] studies using human hepatocytes and liver microsomes have identified the cytochrome P450 (CYP) enzymes CYP3A4 and, to a lesser extent, CYP2C9 as the primary mediators of its oxidative metabolism. Other metabolic pathways, such as glucuronidation, are also believed to play a significant role in its clearance.

Excretion: The elimination of AZD-5069 and its metabolites occurs through both renal and fecal pathways. Following a single oral dose of [$^{14}$C]AZD-5069, complete recovery of radioactivity (mean 100%) was achieved, with approximately 65% of the dose excreted in the urine and 35% in the feces. The plasma concentration of AZD-5069 declines in a multi-exponential manner, with an apparent terminal elimination half-life (T$_{½}$) of approximately 10 to 11 hours. This half-life is consistent with and supports a twice-daily (BID) dosing regimen to maintain steady-state concentrations.

Dose Proportionality and Variability: AZD-5069 exhibits linear pharmacokinetics, with systemic exposure (both AUC and C$_{max}$) increasing in approximate proportion to the dose over the ranges studied. Following a BID dosing schedule, steady-state plasma concentrations are reached within 2 to 3 days, with minimal drug accumulation (accumulation ratio of ~1.1-fold). Intra-subject variability in exposure is low (coefficient of variation for AUC ranging from 3-11%), while inter-subject variability is moderate (29-64%).

Drug-Drug Interactions (DDI): Given its metabolism by CYP3A4, a DDI study was conducted with ketoconazole, a potent inhibitor of this enzyme. Co-administration of AZD-5069 with ketoconazole resulted in a 2.1-fold increase in AUC and a 1.6-fold increase in C$_{max}$ of AZD-5069. This indicates that co-administration with strong CYP3A4 inhibitors will increase exposure to AZD-5069 and requires consideration in clinical practice. Conversely, co-administration with strong CYP3A4 inducers, such as enzalutamide, is expected to decrease exposure, a factor that was accounted for in the dose-finding portion of the ACE trial in prostate cancer.

Parameter	Value / Observation	Source(s)
Absorption
T$_{max}$ (fasting)	~2 hours
Effect of High-Fat Meal	C$_{max}$ decreased by 50%; AUC unchanged
Distribution
Plasma Protein Binding	99%
Apparent Volume of Distribution (V$_{z}$/F)	56 - 134 L
Metabolism
Primary Metabolic Pathways	Oxidative metabolism via CYP3A4 and CYP2C9; Glucuronidation
Excretion
Terminal Half-life (T$_{½}$)	~11 hours
Routes of Excretion	65% renal, 35% fecal (total radioactivity)
Steady-State Kinetics
Time to Steady-State (BID)	2-3 days
Accumulation Ratio (BID)	~1.1-fold
Special Populations & DDIs
Elderly vs. Younger Adults	39% higher AUC and 21% higher C$_{max}$ in elderly
Japanese vs. Caucasian Subjects	Similar or slightly higher exposure in Japanese subjects
DDI with Ketoconazole (CYP3A4 inhibitor)	2.1-fold increase in AUC; 1.6-fold increase in C$_{max}$

VI. Clinical Development in Inflammatory Respiratory Diseases: The Efficacy Paradox

The initial clinical development program for AZD-5069 was logically directed at chronic respiratory diseases characterized by prominent neutrophilic inflammation. The central therapeutic hypothesis was that by inhibiting CXCR2-mediated neutrophil recruitment into the airways, AZD-5069 would reduce inflammation, alleviate symptoms, and prevent disease exacerbations. While Phase II trials across three distinct diseases—COPD, bronchiectasis, and asthma—successfully validated the drug's biological mechanism of action, they uniformly failed to demonstrate clinical benefit, revealing a critical disconnect between the targeted biomarker and disease outcomes.

6.1. Chronic Obstructive Pulmonary Disease (COPD)

A 4-week, Phase IIa study (NCT01233232) was conducted to evaluate the safety and tolerability of AZD-5069 in patients with moderate-to-severe COPD. Patients were randomized to receive placebo, AZD-5069 50 mg BID, or AZD-5069 80 mg BID. The study's primary focus was on safety. The results showed that AZD-5069 was well tolerated, with the incidence of adverse events being similar to or lower than placebo. Importantly, there was no increase in the rate of infections in the active treatment groups compared to placebo. As expected from its mechanism, the drug induced a dose-dependent and reversible reduction in peripheral blood neutrophil counts. However, this study was not designed to assess efficacy, and no data on clinical outcomes like lung function or exacerbation rates were reported.

6.2. Bronchiectasis

The therapeutic potential of AZD-5069 was also tested in patients with non-cystic fibrosis bronchiectasis, another condition defined by neutrophilic airway inflammation. A 28-day, Phase IIa, proof-of-concept study (NCT01255592) randomized patients to receive either AZD-5069 80 mg BID or placebo. The primary endpoint was the change in absolute sputum neutrophil count.

The trial successfully met its primary pharmacodynamic objective. Treatment with AZD-5069 resulted in a statistically significant and biologically profound 69% reduction in the absolute neutrophil count in morning sputum compared to placebo (p=0.004). This result provided unequivocal evidence of target engagement and biological activity in the target organ. Despite this potent effect on the key inflammatory cell, the study found no associated improvements in clinical outcomes. There were no significant changes in lung function, patient-reported symptoms, or health-related quality of life. While the overall number of infections or exacerbations was similar between the two groups, such events led to a higher rate of study discontinuation in the AZD-5069 arm (four vs. zero), suggesting that in the context of an active infection, blunting the neutrophil response might be detrimental.

6.3. Asthma

The largest and most definitive study in the respiratory program was the NIMBUS trial (NCT01704495), a 6-month, Phase II study in patients with uncontrolled, persistent asthma despite treatment with medium-to-high dose inhaled corticosteroids and long-acting beta-agonists. Patients were randomized to placebo or one of three doses of AZD-5069 (5, 15, or 45 mg BID). Pharmacokinetic modeling estimated that the highest dose (45 mg BID) would provide greater than 96% receptor occupancy at trough plasma levels, ensuring robust target engagement throughout the dosing interval.

The results of the NIMBUS trial were unequivocally negative. AZD-5069 failed to meet its primary and secondary efficacy endpoints. There was no reduction in the rate of asthma exacerbations, nor were there any improvements in forced expiratory volume in 1 second (FEV$_{1}$) or total asthma symptom scores at any of the doses tested. An ancillary, exploratory study in a small number of patients with specifically neutrophilic asthma (NCT01890148) did confirm that AZD-5069 treatment reduced neutrophil counts simultaneously in the bronchial mucosa, sputum, and blood, further reinforcing that the drug was performing as expected mechanistically.

The consistent pattern of results across these three distinct but related diseases pointed to a fundamental flaw not in the drug itself, but in the therapeutic hypothesis that underpinned its development for these conditions. The initial premise was that CXCR2-mediated neutrophil recruitment was a primary and modifiable driver of the clinical manifestations of these diseases. The AZD-5069 trials served as a rigorous and definitive test of this premise. The drug successfully engaged its target and modulated the downstream biomarker (airway neutrophils) with high potency. The subsequent and uniform failure to impact clinical outcomes strongly refutes the initial hypothesis. This suggests that in the complex pathophysiology of chronic respiratory diseases, the presence of neutrophils may be more of an epiphenomenon or a marker of underlying disease severity rather than the direct, causal driver of symptoms and exacerbations. The critical pathology may be driven by other immune pathways, structural damage, or neutrophil functions that are not dependent on CXCR2-mediated recruitment. The experience with AZD-5069 in respiratory medicine stands as a landmark case study in drug development, highlighting the peril of relying on a strong biomarker association without a confirmed causal link to clinical outcomes. This outcome, while disappointing for respiratory medicine, provided a well-characterized molecule with a known safety profile, paving the way for its redeployment in oncology, where the role of CXCR2-recruited cells is more directly implicated in disease progression.

VII. Repurposing for Oncology: Clinical Investigations in Malignancies

7.1. Rationale: Targeting the Tumor Microenvironment by Inhibiting Myeloid Cell Recruitment

The strategic pivot of AZD-5069 from inflammatory diseases to oncology is grounded in a sophisticated understanding of the tumor microenvironment (TME). It is now well-established that tumors are not just masses of malignant cells, but complex ecosystems involving various non-cancerous cells, including immune cells, fibroblasts, and endothelial cells. Within this ecosystem, the CXCR2-CXCL signaling axis plays a pivotal, pro-tumorigenic role by orchestrating the recruitment of immunosuppressive myeloid cells.

Two key myeloid cell populations, tumor-associated neutrophils (TANs) and myeloid-derived suppressor cells (MDSCs), express high levels of CXCR2. Tumors frequently secrete CXCR2 ligands (e.g., CXCL1, CXCL8), creating a chemotactic gradient that draws these cells from the circulation and bone marrow into the TME. Once within the tumor, these cells execute a range of functions that support cancer progression: they suppress the activity of cytotoxic T-lymphocytes, promote angiogenesis, facilitate invasion and metastasis, and, critically, contribute to resistance against a wide array of anti-cancer therapies, including chemotherapy, radiotherapy, hormone therapy, and immune checkpoint inhibitors.

The therapeutic hypothesis for AZD-5069 in oncology is therefore not to kill cancer cells directly, but to remodel the TME. By blocking CXCR2, AZD-5069 is intended to inhibit the recruitment of TANs and MDSCs into the tumor. This is expected to alleviate the immunosuppressive environment, "reawakening" the patient's own anti-tumor immune response and, most importantly, re-sensitizing the tumor to other forms of treatment. AZD-5069 is thus positioned as a combination agent designed to break therapeutic resistance.

7.2. Metastatic Castration-Resistant Prostate Cancer (mCRPC): The ACE Trial (NCT03177187)

The first major clinical test of this hypothesis was the ACE trial, a Phase I/II study evaluating AZD-5069 in combination with the androgen receptor antagonist enzalutamide for patients with mCRPC who had already progressed on a novel anti-androgen therapy.

The study design involved a Phase I dose-escalation part to determine the recommended Phase II dose (RP2D) and a Phase II part to evaluate efficacy. The results presented from the trial, primarily from the Phase I portion involving 15-21 evaluable patients, were highly encouraging. The combination was found to be safe and tolerable, with no dose-limiting toxicities observed at AZD-5069 doses up to 320 mg BID. The most common grade 3-4 treatment-emergent adverse event (TEAE) was uncomplicated, reversible neutropenia, an expected on-target effect of the drug.

Most importantly, the combination demonstrated clear signs of clinical activity in this heavily pre-treated, resistant patient population. Partial responses (PR), defined as tumor shrinkage of over 30%, were observed in 2 of 15 response-evaluable patients, while stable disease (SD) was achieved in 10 of 15 patients, with some responses lasting over 16 months. The responses were corroborated by substantial reductions in prostate-specific antigen (PSA) levels. In one notable case, a patient who had previously progressed on multiple lines of therapy achieved a PR with a 31% reduction in target lesion size and an 89% reduction in PSA, with the response lasting for 11 months. The ACE trial provided the first human proof-of-concept that blocking intratumoral myeloid infiltration via CXCR2 inhibition can reverse endocrine resistance and elicit meaningful anti-tumor responses in mCRPC.

7.3. Advanced Hepatocellular Carcinoma (HCC): The CUBIC Trial (2020-003346-36)

Building on strong preclinical data, the CUBIC trial was initiated to investigate AZD-5069 in combination with the anti-PD-L1 immune checkpoint inhibitor durvalumab in patients with advanced HCC. The rationale is particularly strong in this indication, as HCC, especially when associated with NASH, is often characterized by high neutrophil infiltration and a poor response to immunotherapy alone.

This multi-center Phase I/II study employs a dose-escalation design to determine the RP2D of AZD-5069 with a fixed dose of durvalumab, followed by a dose-expansion phase to assess anti-tumor efficacy. The trial includes extensive translational research, with mandatory pre- and on-treatment biopsies to analyze biomarkers of CXCR2 inhibition and changes in the TME's immune cell composition. As of late 2022, the trial was actively recruiting, with the first dose cohort having been completed without any dose-limiting toxicities, indicating that the combination is feasible and safe to administer.

7.4. Other Solid Malignancies (NCT02499328)

The potential applicability of AZD-5069 across different tumor types is being explored in a Phase Ib/II study (NCT02499328). This trial assesses the safety and preliminary efficacy of AZD-5069 in combination with durvalumab in patients with various advanced solid malignancies. A specific dose-expansion cohort is dedicated to patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN), a tumor type where myeloid infiltration is also implicated in pathogenesis and immunotherapy resistance. This study is currently listed as active but not recruiting, suggesting that the initial dose-finding phases may be complete and data analysis is underway.

VIII. Safety, Tolerability, and Immunomodulatory Profile

8.1. Consolidated Safety Data from Human Studies

AZD-5069 has been administered to a substantial number of human subjects, including over 214 healthy volunteers in Phase I studies and hundreds of patients across multiple Phase II trials in both respiratory and oncologic indications. Across this extensive clinical experience, the drug has demonstrated a consistent and generally favorable safety and tolerability profile.

In healthy volunteer studies, single oral doses up to 200 mg and multiple twice-daily doses up to 100 mg were administered with no clinically significant adverse effects observed. In patient populations, the majority of reported adverse events (AEs) have been mild or moderate in severity. For example, in the Phase IIa study in COPD, the overall incidence of AEs in the AZD-5069 groups was comparable to or lower than that in the placebo group. Similarly, in the ACE trial in mCRPC, TEAEs such as fatigue, nausea, and anemia were reported, but no patient discontinued treatment due to a treatment-related AE.

8.2. Characterization of On-Target Neutropenia

The most common and clinically relevant AE associated with AZD-5069 is a dose-dependent reduction in peripheral blood neutrophil counts. This is not an unexpected toxicity but rather a predictable, on-target pharmacologic effect stemming directly from the drug's mechanism of action. By blocking CXCR2, AZD-5069 inhibits the migration of neutrophils from the bone marrow into the systemic circulation, leading to a lower count in the blood.

This neutropenia has been consistently observed across studies. In the COPD trial, blood neutrophil counts decreased from baseline by an average of 14-40% in the 50 mg group and 13-36% in the 80 mg group. In the ACE trial, grade 3-4 neutropenia was the main TEAE, occurring in a dose-dependent manner. A key characteristic of this effect is its rapid reversibility. Upon cessation of treatment, circulating neutrophil levels have been shown to recover and return to baseline values, typically within 7-10 days. This manageable and reversible nature is a critical safety feature.

8.3. The Critical Finding: Preserved Host Immunity

Perhaps the most significant aspect of AZD-5069's safety profile is the consistent observation that the on-target reduction in neutrophil counts does not translate into an increased risk of infections. This has been a consistent finding across placebo-controlled trials in COPD, asthma, and bronchiectasis, where infection rates in the AZD-5069 arms were not higher than in the placebo arms.

[This clinical finding is strongly supported by both preclinical toxicology and dedicated human mechanistic studies. As detailed previously, long-term studies in monkeys showed no increase in infection risk despite high drug exposures. A dedicated Phase I study in healthy volunteers (NCT01480739) was designed specifically to investigate this question. In this study, even while on treatment with AZD-5069, subjects were able to mount a robust neutrophilic response to physiological challenges. Subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) caused a substantial increase in blood neutrophil counts, demonstrating that the bone marrow reserve remains intact and can be mobilized. Furthermore, neutrophils isolated from subjects during treatment retained their full capacity for essential antimicrobial functions, including phagocytosis of ][E. coli] and the production of superoxide anions (oxidative burst).

Together, these data provide a comprehensive picture of AZD-5069's immunomodulatory effects. It selectively inhibits CXCR2-mediated neutrophil trafficking, which is central to chronic, sterile inflammation and TME formation, but it spares the non-CXCR2-mediated pathways that are critical for mobilizing neutrophils and executing antimicrobial functions in response to pathogenic threats. This mechanistic selectivity is the key to its favorable safety profile and is what makes it a viable candidate for long-term administration and combination therapy in cancer patients.

IX. Synthesis and Future Outlook

9.1. Lessons from a Bifurcated Development Path

The development history of AZD-5069 is a powerful illustration of modern, mechanism-based drug discovery and the importance of rigorously testing therapeutic hypotheses. The initial program in respiratory diseases was predicated on the logical, yet ultimately incorrect, assumption that the prominent neutrophilic inflammation in these conditions was a primary driver of clinical pathology. The clinical trials were well-designed and executed, and the drug performed exactly as intended from a pharmacological perspective: it potently and selectively blocked its target and reduced the key biomarker, airway neutrophils. The failure of this program was not a failure of the molecule, but a definitive refutation of the underlying hypothesis. This outcome, while disappointing, provided invaluable knowledge about the pathophysiology of these diseases and a well-characterized drug with a known safety profile.

The subsequent pivot to oncology represents a more sophisticated application of the drug's mechanism. In cancer, the recruitment of CXCR2-expressing myeloid cells is not merely a marker of disease but is mechanistically and causally linked to a key driver of progression: therapeutic resistance. By targeting this specific, causal pathway, the oncology program represents a superior alignment of the drug's mechanism with the underlying biology of the disease. The early success in the ACE trial for mCRPC validates this strategic re-evaluation and highlights the value of deep mechanistic understanding in navigating the complexities of drug development.

9.2. Potential of AZD-5069 as a Combination Therapy in Oncology

The future of AZD-5069 in oncology lies not as a monotherapy, but as a crucial component of combination regimens. Its mechanism of action is not primarily cytotoxic to cancer cells but is instead aimed at remodeling the TME to make it more susceptible to other treatments. Its potential as a "resistance-breaker" and a "synergy-enabler" is substantial.

• With Immune Checkpoint Inhibitors (ICIs): As demonstrated in the CUBIC trial rationale, AZD-5069 can potentially convert immunologically "cold" tumors, which are infiltrated by immunosuppressive myeloid cells, into "hot" tumors that are more responsive to ICIs like anti-PD-1/PD-L1 antibodies.
• With Hormone Therapies: The ACE trial provided direct evidence that AZD-5069 can re-sensitize prostate cancers to androgen receptor antagonists, likely by disrupting the myeloid cells that produce androgens or other survival signals within the TME.
• With Chemotherapy and Radiotherapy: Preclinical data suggest that by blocking the influx of myeloid cells that mediate repair and promote survival after cytotoxic insults, AZD-5069 could enhance the efficacy of traditional chemotherapy and radiation.

9.3. Future Directions and Unanswered Questions

While the oncology program is promising, several key questions must be addressed to optimize the future development of AZD-5069.

• Biomarker Strategy: A critical next step is the development of a robust predictive biomarker strategy. It will be essential to identify which patients are most likely to benefit from CXCR2 inhibition. Potential biomarkers could include high expression of CXCR2 ligands (e.g., CXCL8) in the tumor, a high degree of TAN or MDSC infiltration in pre-treatment biopsies, or specific genetic signatures of the tumor.
• Optimal Dosing and DDI Management: The pharmacokinetic interaction with CYP3A4 modulators presents a clinical challenge. The ACE trial was terminated by the sponsor before the 320 mg dose could be fully explored in the context of co-administration with enzalutamide, a CYP3A4 inducer. Defining the optimal biological dose for TME modulation, especially when combined with drugs that alter its metabolism, will be critical for future studies.
• Expansion to Other Cancers: The biological rationale for CXCR2 inhibition extends to numerous other malignancies. Based on preclinical data and the development programs of other CXCR2 antagonists, logical next steps for investigation could include pancreatic cancer, triple-negative breast cancer, non-small cell lung cancer, and melanoma, among others where myeloid infiltration is a known resistance mechanism.

9.4. Concluding Perspective

AZD-5069 stands as a well-characterized, potent, and selective CXCR2 antagonist with a unique and informative development history. Its failure in respiratory medicine provided a crucial lesson on the difference between biomarker modulation and clinical efficacy. Its rebirth as an oncology agent demonstrates the power of applying a deep mechanistic understanding to a more suitable pathological context. With promising early clinical data in prostate cancer and a strong scientific rationale for its use in combination with immunotherapy and other agents, AZD-5069 is poised to potentially become a valuable new tool in the armamentarium against cancer. Its ultimate success will depend on the careful execution of ongoing and future clinical trials, with a particular focus on patient selection through predictive biomarkers and the optimization of combination strategies. The journey of AZD-5069 exemplifies the dynamic and science-driven nature of modern pharmaceutical development.

Works cited

1. C-X-C chemokine receptor type 2 | DrugBank Online, accessed October 25, 2025, https://go.drugbank.com/bio_entities/BE0010516
2. Expanding role of CXCR2 and therapeutic potential of CXCR2 ..., accessed October 25, 2025, https://www.researchgate.net/publication/368340878_Expanding_role_of_CXCR2_and_therapeutic_potential_of_CXCR2_antagonists_in_inflammatory_diseases_and_cancers
3. Ligand-based pharmacophore model for the discovery of novel CXCR2 antagonists as anti-cancer metastatic agents | Royal Society Open Science - Journals, accessed October 25, 2025, https://royalsocietypublishing.org/doi/10.1098/rsos.180176
4. AZD-5069 (CAS 878385-84-3) - Abcam, accessed October 25, 2025, https://www.abcam.com/en-us/products/biochemicals/azd-5069-ab285434
5. CXCR2 Antagonist RIST4721 Acts as a Potent Chemotaxis Inhibitor of Mature Neutrophils Derived from Ex Vivo-Cultured Mouse Bone Marrow - PMC - NIH, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9953560/
6. Azd-5069 | C18H22F2N4O5S2 | CID 56645576 - PubChem, accessed October 25, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/56645576
7. Definition of CXC chemokine receptor 2 antagonist AZD5069 - NCI ..., accessed October 25, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cxc-chemokine-receptor-2-antagonist-azd5069
8. The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates - NIH, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5286957/
9. AZD-5069 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed October 25, 2025, https://synapse.patsnap.com/drug/cc65791cba4041c5bb10ad69a3b1ca6f
10. What CXCR2 antagonists are in clinical trials currently?, accessed October 25, 2025, https://synapse.patsnap.com/article/what-cxcr2-antagonists-are-in-clinical-trials-currently
11. AZD-5069 | CAS#878385-84-3 | CXCR2 antagonist - MedKoo Biosciences, accessed October 25, 2025, https://www.medkoo.com/products/6904
12. Discovery and Evaluation of a Novel Monocyclic Series of CXCR2 Antagonists, accessed October 25, 2025, https://www.researchgate.net/publication/272395970_Discovery_and_Evaluation_of_a_Novel_Monocyclic_Series_of_CXCR2_Antagonists
13. 'Reprogramming' immune cells could switch defence into attack to ..., accessed October 25, 2025, https://www.icr.ac.uk/about-us/icr-news/detail/reprogramming-immune-cells-could-switch-defence-into-attack-to-treat-prostate-cancer
14. Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers - PMC, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5995788/
15. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions - NIH, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4693488/
16. AZD5069 | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 25, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8948
17. azd 5069 | C18H22F2N4O5S2 | CID 59558839 - PubChem - NIH, accessed October 25, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/59558839
18. AZD 5069 (CAS Number: 878385-84-3) | Cayman Chemical, accessed October 25, 2025, https://www.caymanchem.com/product/28297/azd-5069
19. AZD5069 - AstraZeneca Open Innovation, accessed October 25, 2025, https://openinnovation.astrazeneca.com/clinical-research/clinical-molecules/azd5069.html
20. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/25736418/
21. The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates | Haematologica, accessed October 25, 2025, https://www.haematologica.org/article/view/7989
22. AZD-5069 | CXCR2 Antagonist - MedchemExpress.com, accessed October 25, 2025, https://www.medchemexpress.com/AZD-5069.html
23. A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination ..., accessed October 25, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.TPS631
24. Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma - NIH, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7380483/
25. Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers - ResearchGate, accessed October 25, 2025, https://www.researchgate.net/publication/325480406_Pharmacokinetics_of_the_Oral_Selective_CXCR2_Antagonist_AZD5069_A_Summary_of_Eight_Phase_I_Studies_in_Healthy_Volunteers
26. Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/29856004/
27. Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069 ..., accessed October 25, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995788/
28. The absorption, distribution, metabolism and excretion (ADME) of single oral doses of AZD5069, a novel CXCR2 antagonist, in healthy male volunteers - ERS Publications, accessed October 25, 2025, https://publications.ersnet.org/content/erj/40/suppl56/p2149
29. The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteers - ERS Publications, accessed October 25, 2025, https://publications.ersnet.org/content/erj/40/suppl56/p4842
30. AZD5069 plus enzalutamide is shown to be active in mCRPC, accessed October 25, 2025, https://dailyreporter.esmo.org/esmo-congress-2022/news/the-cxcr2-antagonist-azd5069-plus-enzalutamide-is-shown-to-be-active-in-mcrpc
31. AZD-5069 Completed Phase 2 Trials for Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD) / Laymen Terminology Chronic Bronchitis and Emphysema Treatment - DrugBank, accessed October 25, 2025, https://go.drugbank.com/drugs/DB16822/clinical_trials?conditions=DBCOND0049290%2CDBCOND0049289&phase=2&purpose=treatment&status=completed
32. Search for AZD5069 - Clinical Trials register, accessed October 25, 2025, https://www.clinicaltrialsregister.eu/ctr-search/search?query=AZD5069
33. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/25681277/
34. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis - ERS Publications, accessed October 25, 2025, https://publications.ersnet.org/content/erj/early/2015/09/04/13993003.00148-2015.full.pdf
35. A randomised, placebo-controlled study of the CXCR2 antagonist ..., accessed October 25, 2025, https://publications.ersnet.org/content/erj/46/4/1021
36. Clinical Trial Evaluates CXCR2 antagonist AZD5069 Effect on ..., accessed October 25, 2025, https://bronchiectasisnewstoday.com/2015/10/06/clinical-trial-evaluates-cxcr2-antagonist-azd5069-effect-neutrophil-recruitment-bronchiectasis/
37. NCT01704495 | A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma. | ClinicalTrials.gov, accessed October 25, 2025, https://www.clinicaltrials.gov/study/NCT01704495
38. Neutrophils in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist AZD5069 - An explorative study in neutrophilic asthma - ERS Publications, accessed October 25, 2025, https://publications.ersnet.org/content/erj/48/suppl60/pa4892
39. Distribution of neutrophils in bronchial mucosal tissue in asthma ..., accessed October 25, 2025, https://www.astrazenecaclinicaltrials.com/study/D3551C00003/
40. Study Results | NCT01890148 | Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069 | ClinicalTrials.gov, accessed October 25, 2025, https://clinicaltrials.gov/study/NCT01890148?tab=results
41. CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer - Frontiers, accessed October 25, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.862125/full
42. Scientists discover way to reverse drug resistance in prostate cancer ..., accessed October 25, 2025, https://pmlive.com/pharma_news/scientists_discover_way_to_reverse_drug_resistance_in_prostate_cancer_1502266/
43. ACE: A PhaseI/II trial of AZD5069 in combination with enzalutamide, accessed October 25, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/ace-a-phaseiii-trial-of-azd5069-in-combination-with-enzalutamide/
44. Study Details | NCT03177187 | Combination Study of AZD5069 and ..., accessed October 25, 2025, https://www.clinicaltrials.gov/study/NCT03177187
45. A trial of AZD5069 and durvalumab for cancer that started in the liver ..., accessed October 25, 2025, https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-azd5069-and-durvalumab-for-cancer-that-started-in-the-liver-cubic
46. Durvalumab Active Not Recruiting Phase 1 Trials for Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck Treatment - DrugBank, accessed October 25, 2025, https://go.drugbank.com/drugs/DB11714/clinical_trials?conditions=DBCOND0081444&phase=1&purpose=treatment&status=active_not_recruiting
47. NCT02499328 | Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck | ClinicalTrials.gov, accessed October 25, 2025, https://www.clinicaltrials.gov/study/NCT02499328
48. AZD-5069 Completed Phase 1 Trials for Chemokine Receptor 2 (CXCR2) Antagonist Basic Science - DrugBank, accessed October 25, 2025, https://go.drugbank.com/drugs/DB16822/clinical_trials?conditions=DBCOND0054890&phase=1&purpose=basic_science&status=completed
49. AZD5069 Neutrophil Function Study - AstraZeneca Clinical Trials, accessed October 25, 2025, https://www.astrazenecaclinicaltrials.com/study/D3550C00017/
50. Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro - NIH, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11729135/